Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Case Reports in Obstetrics and Gynecology
|
January 16, 2013
Malignant melanoma of the urethra: a rare histologic subdivision of vulvar cancer with a poor prognosis
Veronika Günther, I Alkatout, C Lez, et al.
Minerva Ginecologica
|
September 21, 2013
Surgical impact of new treatments in breast cancer
I Alkatout, B Order, W Klapper, et al.
Hamostaseologie
|
October 17, 2007
[Coagulation and formation of malignant effusions]
F Gieseler, B Stelck, L-F Blume, et al.
Geburtshilfe Und Frauenheilkunde
|
February 9, 2016
Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey
M T van Mackelenbergh, C M Lindner, T Heilmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2001
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin
C Mundhenke, J P Thomas, G Wilding, et al.
Anticancer Research
|
August 5, 2010
Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer
D O Bauerschlag, M Habermann, J Weimer, et al.
European Journal of Radiology
|
September 24, 2009
Breast ultrasound elastography--results of 193 breast lesions in a prospective study with histopathologic correlation
F K W Schaefer, I Heer, P J Schaefer, et al.
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group
J Barinoff, A Traut, D Bauerschlag, et al.
ESMO Open
|
November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
M Schmidt, K Lübbe, T Decker, et al.
ESMO Open
|
June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
M Schmidt, M Thill, J Rey, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Case Reports in Obstetrics and Gynecology
|
January 16, 2013
Malignant melanoma of the urethra: a rare histologic subdivision of vulvar cancer with a poor prognosis
Veronika Günther, I Alkatout, C Lez, et al.
Minerva Ginecologica
|
September 21, 2013
Surgical impact of new treatments in breast cancer
I Alkatout, B Order, W Klapper, et al.
Hamostaseologie
|
October 17, 2007
[Coagulation and formation of malignant effusions]
F Gieseler, B Stelck, L-F Blume, et al.
Geburtshilfe Und Frauenheilkunde
|
February 9, 2016
Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey
M T van Mackelenbergh, C M Lindner, T Heilmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2001
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin
C Mundhenke, J P Thomas, G Wilding, et al.
Anticancer Research
|
August 5, 2010
Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer
D O Bauerschlag, M Habermann, J Weimer, et al.
European Journal of Radiology
|
September 24, 2009
Breast ultrasound elastography--results of 193 breast lesions in a prospective study with histopathologic correlation
F K W Schaefer, I Heer, P J Schaefer, et al.
Geburtshilfe Und Frauenheilkunde
|
April 29, 2014
Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group
J Barinoff, A Traut, D Bauerschlag, et al.
ESMO Open
|
November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
M Schmidt, K Lübbe, T Decker, et al.
ESMO Open
|
June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
M Schmidt, M Thill, J Rey, et al.
Page
of 3